

Enamine Fsp³-enriched Fragments

1817 compounds

Deliverable as entire set or as selected compounds.

The utilization of fragment based drug discovery (FBDD) approach has already been proved by more than 30 compounds entering the clinic [1]. Among the main focuses of FBDD are Fsp³enriched fragments. Since introduction of the concept "Escape from Flatland" in 2009 implying in the increase of saturation fraction Fsp³ (Fsp³ = ratio of sp³ hybridized carbons *vs* total carbon count) and presence of (potential) chiral centers in libraries [2] numerous MedChem projects directed on the design and screening of more saturated fragments have been appeared [3-5]. Recently the improvement of binding selectivity and frequency toward a set of 100 proteins for diverse small molecules with high ratio of sp³-hybridized and stereogenic atoms have been shown [4].

Considering the needs for new Fsp^3 -enriched fragments **Enamine Fsp^3-enriched Fragment** library was designed from our screening and building blocks collections. Beside the "Rule of three" requirements identifying the fragments [6] the criterion $Fsp^3 > 0.4$ as well as internal Enamine structural filters (including PAINS [7]) were applied.

Parameter	Enamine Fsp ³ -	$ \boxed{ \begin{array}{c} \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\$
	enriched Fragments	
MW	140 300	Z1239043252
HAC	9 22	Z1201627054
	(88.2 % <19 HA)	$N \qquad NH_2 \qquad NH_2$
clogP	-1 3	
HBD	≤ 3	
HBA	≤ 3	Z1753456271
RotB	≤ 3	N Z2049877279
TPSA, Å	≤ 90	
Chiral centers	≤ 2	7722076156
Purity	90+ %	E 210/9132/94 F 2131819/505
Availability	10 mg	Figure 1. Representative set of Fsp ³ -enriched Fragments.

Enamine Fsp³-enriched Fragments are characterized by high structural diversity (the diversity coefficient is **0.89**) including novel compounds with spiro-, bridged, fused rings (see Figure 2) and are described with **1276** different Bemis-Murcko loose frameworks [8].





Figure 2. Analysis of structural diversity of Enamine Fsp³-enriched Fragments.










Figure 3. Physical chemical profile for Enamine Fsp³-enriched Fragments.

Novelty, high chemical and structural diversity of Enamine **Fsp³-enriched Fragments** will make easier any search of new ligands for challenging targets.

Also Enamine Golden Fragment Library, general Enamine Fragments as well as different focused fragment libraries (Enamine PPI, Fluorinated, Brominated Fragments) were developed



exploiting the same filters and approaches. Furthermore the database of **Enamine Feasible Fragments** calculating near 465 k compounds and representing the biggest offered on the market "fragment space" was prepared by applying fragment identifying criteria to Enamine REAL DataBase collection. For further information please visit <u>www.enamine.net</u>.

- [1] M. Baker Fragment-Based Lead Discovery Grows Up, Nat. Rev. Drug Discovery 2013, 12(1), 5-7.
- [2] F. Lovering, J. Bikker, C. Humblet Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success, J. Med. Chem. 2009, 52 (21), 6752-6756.
- [3] A. W. Hung, A. Ramek, Y. Wang, T. Kaya, J. A. Wilson, P. A. Clemons, D. W. Young Route to Threedimensional Fragments Using Diversity-Oriented Synthesis, PNAS 2011, 108(17), 6799-6804.
- [4] P. A. Clemons, N. E. Bodycombe, H. A. Carrinski, J. A. Wilson, A. F. Shamji, B. K. Wagner, A. N. Koehler, S. L. Schreiber Small Molecules of Different Origins Have Distinct Distributions of Structural Complexity that Correlate with Protein-binding Profiles, PNAS 2010, 107 (44), 18787-18792.
- [5] N. C. Trana, H. Dhondta, M. Flipoa, B. Depreza, N. Willanda Synthesis of Functionalized 2-Isoxazolines as Three-dimensional Fragments for Fragment-based Drug Discovery, Tetrahedron Lett. 2015, 56 (27), 4119-4123.
- [6] M. Congreve, R. Carr, C. Murray, H. Jhoti A 'Rule of Three' for Fragment-Based Lead Discovery, Drug Discov. Today 2003, 8(19), 876-877.
- [7] J.B. Baell, G.A. Holloway New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays, J. Med. Chem. 2010, 53(7), 2719-2740.
- [8] J.W. Bemis, M.A. Murcko The properties of known drugs. 1. Molecular frameworks, J. Med. Chem. 1996, 39(15), 2887-2893.